FDA-Approved Fluorinated Drugs in 2026: A New Wave of Therapeutic Innovation

FDA-Approved Fluorinated Drugs in 2026. Fluorine substitution has become a widely adopted strategy in medicinal chemistry. Owing to its high electronegativity and small atomic radius, fluorine introduces distinctive electronic and steric effects that can markedly enhance a compound’s lipophilicity, metabolic stability, binding affinity, and pKa modulation. As a result, these improvements often translate into better pharmacokinetic profiles, increased bioavailability, and enhanced therapeutic efficacy, earning fluorine the reputation of a “magic atom.”

A recent review published in CCL, titled “Fluorine-containing drugs approved by the US FDA in 2025” (10.1016/j.cclet.2026.112640), systematically summarizes fourteen newly approved fluorine-containing drugs. These agents span a broad spectrum of therapeutic areas, including oncology (breast cancer, lung cancer, leukemia, and ovarian cancer), acute pain, neurofibromatosis, hereditary angioedema, immune thrombocytopenia, acromegaly, chronic spontaneous urticaria, menopausal vasomotor symptoms, and bacterial infections such as gonorrhea. Collectively, these approvals underscore fluorination as a highly versatile and effective strategy for optimizing drug performance across diverse disease indications.

Fourteen Fluorine-Containing Drugs Approved in 2025

• Datopotamab deruxtecan

Datopotamab deruxtecan (trade name Datroway) received FDA approval on January 17, 2025, for the treatment of unresectable or metastatic hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer in patients who have previously undergone endocrine therapy and chemotherapy. This agent is a TROP2-directed antibody–drug conjugate (ADC), consisting of an anti-TROP2 monoclonal antibody, a cleavable tetrapeptide linker, and a cytotoxic payload based on the topoisomerase I inhibitor exatecan.

The drug exerts its antitumor activity by specifically binding to TROP2 on cancer cells, followed by internalization and intracellular release of exatecan, which induces DNA damage and ultimately leads to tumor cell death. Notably, exatecan is a fluorinated camptothecin analogue, where the incorporation of a fluorine atom enhances cytotoxic potency while helping to mitigate systemic toxicity. This design exemplifies a key strategy in optimizing both the efficacy and safety of ADC payloads.

• Suzetrigine

Suzetrigine (trade name Journavx) is a novel non-opioid analgesic approved by the U.S. FDA on January 30, 2025, for the treatment of moderate to severe acute pain. It acts through selective inhibition of the voltage-gated sodium channel Nav1.8, thereby avoiding the tolerance, dependence, and serious adverse effects commonly associated with opioid analgesics.

Structurally, the molecule is a highly complex pyridine derivative containing a tetrahydrofuran (oxolane) core, four stereocenters, a trifluoromethyl group, and a 3,4-difluoro-2-methoxyphenyl moiety. The incorporation of multiple fluorine atoms is a key feature of its design strategy: by increasing lipophilicity, these substitutions enhance interactions within the hydrophobic binding pocket of the target protein, while also improving metabolic stability. Together, these effects contribute to the optimization of both the pharmacodynamic and pharmacokinetic properties of the drug.

• Mirdametinib

Mirdametinib (trade name Gomekli) is a fluorinated MEK1/2 kinase inhibitor approved by the U.S. FDA on February 11, 2025, for the treatment of patients aged 2 years and older with type 1 neurofibromatosis (NF1) who have symptomatic, inoperable plexiform neurofibromas.

Its mechanism of action involves inhibition of MEK1/2, a key component of the Ras–Raf–MEK–ERK signaling cascade, thereby suppressing tumor cell proliferation. Structurally, mirdametinib is a glyceride-derived benzohydroxamic acid compound featuring a diphenylamine core, with fluorine substituents on both phenyl rings.

Structure–activity relationship studies suggest that these fluorine atoms play a crucial role in enhancing Raf/MEK inhibitory potency by strengthening drug–target interactions. In particular, they are proposed to improve binding affinity within the MEK1 active site through favorable interactions with residues such as Lys97 and Ser212, ultimately contributing to the compound’s optimized biological activity.

• Avutometinib and Defactinib

Avmapki is a co-packaged formulation containing two kinase inhibitors, avutometinib and defactinib, which was approved by the U.S. FDA in May 2025 for the treatment of patients with recurrent low-grade serous ovarian cancer (LGSOC) harboring KRAS mutations who have previously received systemic therapy.

This combination therapy achieves synergistic antitumor activity through dual targeting mechanisms: avutometinib functions as a dual MEK and RAF inhibitor to suppress the MAPK signaling pathway, while defactinib inhibits focal adhesion kinase (FAK) and Pyk2.

Both components incorporate fluorine into their molecular structures as a key design feature. Avutometinib contains a fluorine substituent on its pyridine ring, which contributes to improved lipophilicity and enhanced metabolic stability. Defactinib, on the other hand, includes a trifluoromethyl (CF₃) group on its pyrimidine core, which strengthens binding interactions with FAK, including contacts within the vicinity of Asp564, potentially through halogen bonding. Structurally, avutometinib is based on a 4-methylcoumarin scaffold, while defactinib belongs to the 2,4-diaminopyrimidine class. In both cases, fluorine incorporation represents a central strategy for optimizing pharmacodynamic potency and pharmacokinetic properties.

• Taletrectinib

Taletrectinib (trade name Ibtrozi) is an oral, potent, and selective ROS1 tyrosine kinase inhibitor approved by the U.S. FDA on June 11, 2025, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

It functions by selectively inhibiting the ROS1 receptor tyrosine kinase, thereby blocking downstream signaling pathways that promote tumor proliferation and survival. In addition, taletrectinib also exhibits activity against the neurotrophic tyrosine receptor kinase (NTRK) family and retains efficacy against certain ROS1 resistance mutations that limit the effectiveness of earlier therapies.

From a medicinal chemistry standpoint, the fluorine substituent on the benzene ring is essential for maintaining strong ROS1 inhibitory potency. Structure–activity relationship (SAR) studies indicate that fluorinated analogs achieve markedly improved activity (ROS1 IC₅₀ < 20 nmol/L) compared with their non-fluorinated counterparts, highlighting the importance of fluorine incorporation in optimizing target binding and overall pharmacological performance.

• Sunvozertinib

Sunvozertinib (trade name Zegfrovy) is an oral covalent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Dizal Pharma for the treatment of non-small cell lung cancer (NSCLC). In July 2025, it received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed following platinum-based chemotherapy.

The drug exerts its antitumor effect by irreversibly and covalently binding to the ATP-binding pocket of the EGFR kinase domain, thereby inhibiting downstream signaling pathways that drive tumor cell proliferation and survival.

From a medicinal chemistry perspective, the fluorine atom in its molecular structure plays a key role in optimizing drug–target interactions. By contributing a distinct hydrophobic and electronic profile, it facilitates more effective docking within the hydrophobic pocket of EGFR. This structural feature enhances inhibitory potency (IC₅₀ = 1.1 nmol/L against pEGFR T790M), while also improving metabolic stability and reducing clearance in human hepatocytes.

• Sebetralstat

Sebetralstat (trade name Ekterly) is an oral, small-molecule plasma kallikrein inhibitor approved by the U.S. FDA in July 2025 for the treatment of hereditary angioedema (HAE).

It acts by selectively inhibiting plasma kallikrein, thereby preventing its excessive activation and reducing the production of bradykinin, a key mediator responsible for triggering angioedema attacks. Through this mechanism, sebetralstat helps prevent or alleviate acute tissue swelling.

From a medicinal chemistry perspective, the molecule contains fluorine substituents that contribute to its pharmacological optimization. These fluorine atoms enhance hydrophobic interactions within the target binding pocket and help stabilize preferred molecular conformations via stereoelectronic effects, including the gauche effect. Together, these properties improve the balance between lipophilicity and clearance, enhance membrane permeability, and ultimately support more favorable pharmacokinetic behavior.

• Rilzabrutinib

Rilzabrutinib (trade name Wayrilz) is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor approved by the U.S. FDA on August 29, 2025, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to prior therapies such as immunoglobulins or corticosteroids.

Its mechanism of action involves the reversible inhibition of BTK to modulate aberrant immune signaling. This dual immunoregulatory effect reduces B-cell–mediated autoantibody production against platelets while also limiting macrophage-mediated platelet destruction, thereby helping to restore platelet counts.

From a medicinal chemistry perspective, the presence of a fluorine atom is a key structural feature that contributes to its high potency. This modification enhances BTK inhibitory activity (IC₅₀ = 1.3 nmol/L) and supports strong performance in human whole-blood B-cell activation assays. Overall, rilzabrutinib reflects a shift from irreversible BTK inhibitors originally developed for oncology toward more selective, reversible agents optimized for autoimmune disease treatment.

• Imlunestrant

Imlunestrant (trade name Inluriyo) is an oral selective estrogen receptor degrader (SERD) approved by the U.S. FDA on September 25, 2025, for the treatment of advanced or metastatic breast cancer that is estrogen receptor (ER)–positive, HER2-negative, and harboring ESR1 mutations.

The drug exerts its therapeutic effect by binding to estrogen receptor alpha and promoting its degradation, leading to sustained suppression of receptor signaling and effectively overcoming endocrine resistance driven by ESR1 mutations.

From a structural standpoint, the incorporation of a trifluoromethyl (CF₃) group is a key design element that enhances binding affinity and degradation potency against both wild-type and mutant receptors. Clinically, imlunestrant monotherapy has been shown to prolong progression-free survival while maintaining a favorable safety profile, with commonly reported adverse events limited to mild gastrointestinal symptoms and fatigue. Notably, the compound also demonstrates the ability to penetrate the blood–brain barrier, suggesting potential utility in treating brain metastases and marking an important advance in next-generation endocrine therapy.

• Paltusotine

Paltusotine (trade name Palsonify) is an oral, non-peptide, highly selective somatostatin receptor subtype 2 (SST₂) agonist developed by Crinetics Pharmaceuticals for the treatment of acromegaly in adults who have responded inadequately to surgery or are not candidates for surgical intervention. It exerts its therapeutic effect by suppressing the secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1).

The drug was approved by the U.S. Food and Drug Administration (FDA) on September 25, 2025, representing the first oral, non-peptide SST₂ agonist and offering a significant advancement in acromegaly management.

From a medicinal chemistry perspective, the incorporation of a fluorine atom is essential for preserving the compound’s high potency and receptor selectivity, contributing to its strong and specific binding to the SST₂ receptor.

• Remibrutinib

Remibrutinib (trade name Rhapsido) is a highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor developed by Novartis. It was approved by the U.S. FDA on September 30, 2025, for the treatment of chronic spontaneous urticaria (CSU) in adults who have had an inadequate response to second-generation H1 antihistamines.

The drug exerts its effect by irreversibly inhibiting BTK, a key enzyme involved in the activation of mast cells, basophils, and B cells, thereby reducing the signaling pathways that drive urticaria symptoms.

From a medicinal chemistry standpoint, the incorporation of a fluorine atom is critical for enhancing pharmacological performance. Compared with non-fluorinated analogs, remibrutinib exhibits greater BTK inhibitory potency (IC₅₀ = 1.3 ± 0.9 nmol/L) and improved membrane permeability, which together contribute to its rapid onset and sustained therapeutic effect. Overall, remibrutinib represents a promising oral targeted therapy for immune-mediated conditions driven by mast cells, basophils, and B cells.

• Elinzanetant

Elinzanetant (trade name Lynkuet) is a potent, selective dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist developed by Bayer. It was approved by the U.S. FDA on October 24, 2025, for the treatment of moderate-to-severe vasomotor symptoms, such as hot flashes, associated with menopause.

The drug exerts its therapeutic effects by simultaneously blocking NK1 and NK3 receptors, thereby modulating the neurokinin–kisspeptin system and influencing thermoregulation as well as reproductive hormone signaling pathways.

Clinical studies have shown that elinzanetant significantly reduces the frequency of moderate-to-severe vasomotor symptoms while also improving sleep quality and mood, all with a favorable safety profile. From a medicinal chemistry perspective, the incorporation of fluorine within its molecular structure enhances receptor binding affinity and contributes to improved molecular stability, supporting its overall pharmacological performance.

• Ziftomenib

Ziftomenib (trade name Komzifti) is a first-in-class, potent, and highly selective menin inhibitor developed by Kura Oncology. It received U.S. FDA approval on November 13, 2025, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring susceptible NPM1 mutations.

The drug acts by disrupting the interaction between menin and the MLL1 (mixed-lineage leukemia 1) protein, thereby suppressing key transcriptional programs—such as the HOX and MEIS1 gene clusters—that drive leukemogenesis.

In clinical studies, ziftomenib demonstrated encouraging efficacy, achieving a complete remission rate of 35% in patients with NPM1 mutations. From a medicinal chemistry perspective, the incorporation of a trifluoroethyl (–CF₃) group is a critical design element that enhances target binding affinity and improves metabolic stability, contributing to the compound’s overall pharmacological performance.

• Zoliflodacin

Zoliflodacin (trade name Nuzolvence) is a novel oral antibiotic approved by the U.S. FDA in December 2025 for the treatment of uncomplicated gonorrhea in adults and adolescents (aged ≥12 years and weighing ≥35 kg).

It belongs to the first-in-class spiropyrimidinetrione class and exerts its antibacterial activity by inhibiting bacterial topoisomerase IV, thereby disrupting DNA replication. Zoliflodacin demonstrates potent efficacy against multidrug-resistant Neisseria gonorrhoeae, including strains resistant to ceftriaxone and azithromycin.

Importantly, the drug shows no cross-resistance with existing antibiotic classes such as fluoroquinolones, making it a valuable new option in the fight against antibiotic-resistant gonorrhea and addressing a critical unmet need in infectious disease treatment.

Common Characteristics

The fourteen fluorine-containing drugs approved by the U.S. FDA in 2025 exhibit a striking level of consistency in molecular design. In each case, fluorine atoms or fluorinated groups (such as CF₃) are intentionally incorporated, leveraging fluorine’s high electronegativity and small atomic radius to finely tune lipophilicity, metabolic stability, target binding affinity, and pKa. Collectively, these effects translate into improved efficacy, bioavailability, and overall pharmacokinetic performance.

From a structural perspective, the vast majority of these compounds—apart from three exceptions—are built on heterocyclic scaffolds. This underscores the central role of heterocycles in modern medicinal chemistry, as their diverse electronic properties and conformational flexibility enable precise interactions with biological targets. In parallel, stereochemical control is another defining feature: most of these drugs are chiral and developed as single active enantiomers, enhancing selectivity, improving therapeutic outcomes, and reducing off-target effects.

In terms of fluorination patterns, this group exemplifies four classical strategies. Aromatic monofluorination is the most common, appearing in ten drugs (including exatecan and mirdametinib), where it allows fine adjustment of electronic properties and metabolic stability with minimal steric impact. Aromatic difluorination is observed in suzetrigine, mirdametinib, and paltusotine. Trifluoromethyl substitution, present in defactinib, imlunestrant, and elinzanetant, markedly increases hydrophobicity and helps block metabolic “hotspots.” Finally, aliphatic fluorination—seen in suzetrigine, imlunestrant, and ziftomenib—represents a less common but highly effective strategy for stabilizing C–H bonds and modulating molecular conformation.

Remaining Issues

While newly approved fluorine-containing drugs show substantial therapeutic promise, their safety considerations deserve careful attention. The very metabolic stability imparted by fluorine—one of its greatest advantages—can also present challenges: prolonged persistence in the body may increase the risk of accumulation and long-term toxicity, thereby placing higher demands on safety evaluation for chronic use. In addition, metabolic complexity introduces further uncertainty, as enzymatic processes may induce defluorination, generating metabolites with unknown structures, pharmacological activities, and toxicological profiles. These factors highlight the importance of establishing robust metabolite monitoring and safety assessment systems early in preclinical development.

Looking ahead, the development of next-generation fluorinated drugs offers multiple avenues for innovation. In synthetic chemistry, there is a growing emphasis on developing greener and more efficient fluorination methodologies that reduce environmental impact, improve cost-effectiveness, and enhance operational simplicity, ultimately advancing atom economy and industrial scalability. From a molecular design standpoint, expanding beyond conventional strategies—such as aromatic mono- and difluorination or trifluoromethylation—will be key to unlocking new chemical space. Emerging functional groups like trifluoromethoxy and difluoromethyl moieties, with their distinctive electronic and bioisosteric properties, offer promising opportunities to further optimize lipophilicity, metabolic stability, and target interactions.

At the same time, the integration of artificial intelligence is reshaping drug discovery workflows. Machine learning–driven prediction of optimal fluorination sites can significantly reduce reliance on empirical trial-and-error approaches, accelerating the shift toward data-driven, rational design. Finally, environmental considerations are becoming increasingly important: the exceptional stability of carbon–fluorine bonds raises concerns about persistence in ecosystems. As a result, understanding the degradation pathways, environmental fate, and potential ecotoxicological impacts of fluorinated drugs is emerging as a critical frontier at the intersection of medicinal chemistry, environmental science, and regulatory policy.

Conclusion

The fourteen fluorine-containing drugs approved in 2025 highlight the enduring importance of fluorine in drug discovery. By enabling precise control over molecular properties, fluorination continues to drive innovation across therapeutic areas—while also challenging researchers to balance efficacy, safety, and sustainability.